Antepartum periodontitis treatment and risk of offspring screening positive for autism spectrum disorder

J Perinatol. 2023 Apr;43(4):470-476. doi: 10.1038/s41372-023-01610-x. Epub 2023 Jan 25.

Abstract

Background: To evaluate if treating maternal periodontal disease, a pro-inflammatory condition, during pregnancy (intervention) compared to after pregnancy (control) reduces the likelihood of offspring screening positive for autism spectrum disorder (ASD).

Methods: In a follow-up study to the MOTOR randomized trial, we compared rates of positive screens on the Modified Checklist for Autism in Toddlers (M-CHAT) among n = 306 two-year-old toddlers and correlated findings to maternal and cord blood pro-inflammatory interleukin-6 (IL-6).

Results: Toddlers in the intervention group had decreased risk of a positive M-CHAT screen (adjusted RR = 0.53, 95% CI 0.29-0.99). Toddlers screening positive compared to negative had higher mean IL-6 in cord blood (1.58 ± 1.14 vs. 1.09 ± 0.72 p = 0.001) and maternal IL-6 change from baseline (1.30 ± 0.61 vs 0.96 ± 0.62 p = 0.03).

Conclusions: Treating periodontal disease during pregnancy reduced risk of a positive ASD screen. M-CHAT positivity was associated with increased IL-6 in maternal and cord blood.

Clinical trial: Trial Registration numbers: Clinicaltrials.gov NCT03423836.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Autism Spectrum Disorder* / diagnosis
  • Checklist
  • Follow-Up Studies
  • Humans
  • Infant
  • Interleukin-6
  • Mass Screening
  • Periodontal Diseases*
  • Periodontitis* / diagnosis

Substances

  • Interleukin-6

Associated data

  • ClinicalTrials.gov/NCT03423836